Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
BioNTech SE - American Depositary Shares
(NQ:
BNTX
)
102.18
+2.33 (+2.33%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioNTech SE - American Depositary Shares
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
71
72
Next >
US Stocks Set For Mixed Start This Week On Inflation, Debt Ceiling Worries — But Analyst Sees A 'Turning Point'
↗
May 08, 2023
Caution returned to Wall Street as indicated by the index futures, which traded narrowly mixed early Monday.
Via
Benzinga
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
May 08, 2023
From
BioNTech SE
Via
GlobeNewswire
Earnings Preview For BioNTech
↗
May 05, 2023
Via
Benzinga
The 7 Best Bargain Stocks to Buy for May 2023
↗
May 04, 2023
With inflation crimping everyone’s wallet, these best bargain stocks to buy can make your dollars stretch significantly.
Via
InvestorPlace
How To Attend BioNTech Q1 2023 Earnings Conference Call
↗
April 27, 2023
Via
Benzinga
Buy This Pharma Powerhouse With A 4% Yield
↗
April 21, 2023
Imagine a company whose stock hit an all-time in December 2021 after soaring 50% that year. And that company’s sales doubled in the two years leading up to 2022. And its operating profits quadrupled.
Via
Talk Markets
P/E Ratio Insights for BioNTech
↗
April 20, 2023
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
↗
April 17, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
May 04, 2023
Via
Benzinga
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
↗
May 01, 2023
Benzinga
Via
Benzinga
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
↗
May 01, 2023
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public...
Via
Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
↗
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
What 12 Analyst Ratings Have To Say About BioNTech
↗
April 10, 2023
Via
Benzinga
A Look Into BioNTech Inc's Price Over Earnings
↗
April 03, 2023
Via
Benzinga
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
April 24, 2023
From
BioNTech SE
Via
GlobeNewswire
Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?
↗
April 20, 2023
The company is facing a litigation headwind and continued competition.
Via
Investor's Business Daily
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
↗
April 19, 2023
Make your dollars go as far as possible (and relatively safely) with these low-PE ratio blue-chip stocks to buy.
Via
InvestorPlace
FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid
↗
April 18, 2023
Via
Benzinga
Bear of the Day: BioNTech
↗
March 28, 2023
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines.
Via
Talk Markets
These Analysts Revise Price Targets On BioNTech After Q4 Results
↗
March 28, 2023
BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter.
Via
Benzinga
Why Shares of BioNTech Slumped Monday
↗
March 27, 2023
The company released fourth-quarter earnings.
Via
The Motley Fool
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
↗
April 12, 2023
Via
Benzinga
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
↗
April 11, 2023
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...
Via
Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
↗
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
↗
April 04, 2023
Via
Benzinga
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
April 03, 2023
From
BioNTech SE
Via
GlobeNewswire
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
↗
March 31, 2023
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.
Via
Investor's Business Daily
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
↗
March 28, 2023
B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%...
Via
Benzinga
BioNTech Announces New ADS Repurchase Program
March 28, 2023
From
BioNTech SE
Via
GlobeNewswire
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
71
72
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.